The American Journal of Medicine
Volume 119, Issue 10 , Pages 865-871 , October 2006

Impact of Guideline-Concordant Empiric Antibiotic Therapy in Community-Acquired Pneumonia

  • Christopher R. Frei, PharmD, MSc

      Affiliations

    • University of Texas at Austin College of Pharmacy, Austin, Tex
    • University of Texas Health Science Center at San Antonio, San Antonio, Tex
    • ,
  • Marcos I. Restrepo, MD, MSc

      Affiliations

    • University of Texas Health Science Center at San Antonio, San Antonio, Tex
    • Veterans Evidence-Based Research Dissemination and Implementation Center, San Antonio, Tex
    • South Texas Veterans Health Care System, San Antonio, Tex.
    • ,
  • Eric M. Mortensen, MD, MSc

      Affiliations

    • University of Texas Health Science Center at San Antonio, San Antonio, Tex
    • Veterans Evidence-Based Research Dissemination and Implementation Center, San Antonio, Tex
    • South Texas Veterans Health Care System, San Antonio, Tex.
    • ,
  • David S. Burgess, PharmD

      Affiliations

    • University of Texas at Austin College of Pharmacy, Austin, Tex
    • University of Texas Health Science Center at San Antonio, San Antonio, Tex
    • Corresponding Author InformationRequests for reprints should be addressed to David S. Burgess, PharmD, Clinical Pharmacy Programs-MSC 6220, The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900.

References 

  1. Minino AM, Arias E, Kochanek KD, et al. Deaths: final data for 2000. Natl Vital Stat Rep. 2002;50:1–119
  2. Kozak LJ, Hall MJ, Owings MF. National Hospital Discharge Survey: 2000 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2002;13:1–194
  3. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med. 2002;166:717–723
  4. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820–837
  5. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405–1433
  6. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia (Diagnosis, assessment of severity, antimicrobial therapy, and prevention). Am J Respir Crit Care Med. 2001;163:1730–1754
  7. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399–1408
  8. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159:2562–2572
  9. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001;119:1420–1426
  10. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med. 2004;117:726–731
  11. Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med. 1999;159:2576–2580
  12. Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med. 2001;161:61–65
  13. Lentino JR, Krasnicka B. Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. Int J Antimicrob Agents. 2002;19:61–66
  14. WHO Collaborating Centers. International classification of diseases. Epidemiol Bull. 1998;19:7–11
  15. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452–1457
  16. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250
  17. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273–1276
  18. Niederman MS, Bass JB, Campbell GD, et al. American Thoracic Society. Medical section of the American Lung Association Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418–1426
  19. Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America Clin Infect Dis. 1998;26:811–838
  20. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med. 2005;165:1992–2000
  21. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ. 2005;330:456–460
  22. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123:1503–1511
  23. Frei CR, Koeller JM, Burgess DS, et al. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy. 2003;23:1167–1174
  24. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 2000;34:446–452
  25. Trowbridge JF, Artymowicz RJ, Lee CE, et al. Antimicrobial selection and length of hospital stay in patients with community-acquired pneumonia. J Clin Outcomes Manage. 2002;9:613–620
  26. Frei CR, Burgess DS. Cost-effectiveness of 4 empiric antimicrobial regimens in patients with community-acquired pneumonia. Formulary. 2005;40:298–303
  27. Mortensen EM, Restrepo MI, Anzueto AA, Pugh J. The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care. 2005;10:R8
  28. Hospital-acquired pneumonia in adults (diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: A consensus statement, American Thoracic Society, November 1995). Am J Respir Crit Care Med. 1996;153:1711–1725
  29. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416
  30. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637–644

PII: S0002-9343(06)00194-X

doi: 10.1016/j.amjmed.2006.02.014

The American Journal of Medicine
Volume 119, Issue 10 , Pages 865-871 , October 2006

Article Tools